Literature DB >> 27112638

Lipid profiling of lipoprotein X: Implications for dyslipidemia in cholestasis.

Susanne Heimerl1, Alfred Boettcher1, Harald Kaul2, Gerhard Liebisch3.   

Abstract

Lipoprotein X (Lp-X) is an abnormal lipoprotein that may typically be formed in intra- and extrahepatic cholestasis and potentially interfere with lipid analysis in the routine lab. To gain insight into lipid class and species composition, Lp-X, LDL and HDL from cholestatic and control serum samples were subjected to mass spectrometric analysis including phospholipids (PL), sphingolipids, free cholesterol (FC), cholesteryl esters (CE) and bile acids. Our analysis of Lp-X revealed a content of 46% FC, 49% PL with 34% phosphatidylcholine (PC) as main PL component. The lipid species pattern of Lp-X showed remarkable high fractions of mono-unsaturated species including PC 32:1 and PC 34:1 and phosphatidylethanolamine (PE) 32:1 and 34:1. LDL and HDL lipid composition in the same specimens strongly reflected the lipid composition of Lp-X with increased PC 32:1, PC 34:1, PE 32:1, PE 34:1 and FC accompanied by decreased CE compared to controls. Comparison of Lp-X and biliary lipid composition clearly indicates that Lp-X does not originate from a sole release of bile lipids. Moreover, these data present evidence for increased hepatic fatty acid and PL synthesis which may represent a reaction to high hepatic FC level observed during cholestasis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cholestasis; Lipidomics; Lipoproteins; Lp-X; Mass spectrometry

Mesh:

Substances:

Year:  2016        PMID: 27112638     DOI: 10.1016/j.bbalip.2016.04.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency.

Authors:  Boris L Vaisman; Edward B Neufeld; Lita A Freeman; Scott M Gordon; Maureen L Sampson; Milton Pryor; Emily Hillman; Milton J Axley; Sotirios K Karathanasis; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2018-12-18       Impact factor: 4.030

2.  Hypercholesterolemia Due to Lipoprotein X: Case Report and Thematic Review.

Authors:  Laura Kattah; Andrés Gómez; Sebastián Gutiérrez; Kathalina Puerto; Eiman D Moreno-Pallares; Andrés Jaramillo; Carlos O Mendivil
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-09-29

3.  Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Authors:  Shimpi Bedi; Erwin Garcia; Elias J Jeyarajah; Irina Shalaurova; Maria Camila Perez-Matos; Z Gordon Jiang; Robin P F Dullaart; Steven P Matyus; William J Kirk; James D Otvos; W Sean Davidson; Margery A Connelly
Journal:  J Clin Med       Date:  2020-09-10       Impact factor: 4.241

4.  Gastric Xanthomatosis Secondary to Lipoprotein X in Primary Biliary Cholangitis.

Authors:  Erin Petrie; Nicholas A Hoppmann; C Mel Wilcox; Sameer Al Diffalha; Meagan E Gray
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

5.  Case report: Unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis.

Authors:  Rossella Colantuono; Chiara Pavanello; Andrea Pietrobattista; Marta Turri; Paola Francalanci; Marco Spada; Pietro Vajro; Laura Calabresi; Claudia Mandato
Journal:  Front Pediatr       Date:  2022-08-04       Impact factor: 3.569

6.  Transiently Elevated TC and sdLDL-C Levels and Falsely Low LDL-C Levels in Patients with Extrahepatic Cholangiocarcinoma.

Authors:  Yi Guo; Yong-Gen Zhang; Hong-Chun Li; Yin-Hai Xu
Journal:  Onco Targets Ther       Date:  2021-02-15       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.